Acurx Pharmaceuticals (ACXP) stock

Market cap $5.7MShares as of Aug 13

$1.09

-4.41%

As of Monday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score ACXP. It is too small and too thinly traded for a fair Quality Score.

Healthcare · Biotech

Cash$10.7M, about 6 quarters at the last year's spendingOn Jun 30

Follow ACXP's trial news. Pro members can get an alert when Acurx Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ACXP files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,191 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$10.7M, about 6 quarters at the last year's spendingOn Jun 30

What's next for ACXP, and how long its cash lasts

Its trials

A trial underway: ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionPhase 2 · Recruiting · 20 people · main data estimated Sep 29, 2027 · NCT07513285

For Pro members: 23 filings.

Cash runway Jun 30 balance sheet

About 6 quarters

$10.7M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 5 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when David Luci buys or sells

For Pro members: every trade, and David Luci’s 3 filings and quotes.

Get an alert when ACXP files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

ACXP's latest filings

A shareholder vote8-K, filed Oct 16
Prospectus for a sale of securities424B3, filed Sep 17
Quarterly report10-Q, filed Aug 13

15 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why ACXP isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. ACXP is worth about $5.7M and trades about 78,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.